In this review, we summarize the established data from various pediatric cancer-related studies including in vitro, in vivo, and clinical research, and explain all the benefits and potential obstacles of targeting B7-H3 by novel immunotherapeutic agents designed to treat malignant extracranial solid tumors of childhood. Here, CD276 is linked to cancer.